Indication
Stage IIIA Rectal Cancer
4 clinical trials
6 products
5 drugs
Clinical trial
A Phase I Clinical Trial of Trametinib in Combination With TAS-102 in Patients With Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild-Type) Metastatic Colorectal CancerStatus: Completed, Estimated PCD: 2023-07-14
Product
TrametinibProduct
Trifluridine and TipiracilClinical trial
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 AmplificationStatus: Active (not recruiting), Estimated PCD: 2022-11-01
Product
CetuximabProduct
IrinotecanProduct
PertuzumabDrug
TrastuzumabClinical trial
A Randomized Double Blinded Study of Curcumin With Pre-operative Capecitabine and Radiation Therapy Followed by Surgery for Rectal CancerStatus: Terminated, Estimated PCD: 2022-11-11
Drug
UTD1Clinical trial
A Phase I Study of Talimogene Laherparepvec (Talimogene Laherparepvec) With Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the RectumStatus: Terminated, Estimated PCD: 2022-03-22
Drug
fluorouracilDrug
FOLFOXIRIDrug
mFOLFOX6Product
Talimogene Laherparepvec